Alopecia Areata. Alopecia areata
Conditions
Interventions
Intervention 1: Intervention group 1: The first group will be treated with 3 mg betamethasone per oral in the form of 0.5 mg tablets (made by Iran Hormones Co.) and with a dose of 1 mg for breakfast,
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 60 Years
Inclusion criteria
Inclusion criteria: The scalp involvement rate more than 50% The disease is resistant to systemic and topical combination therapy The patient is satisfied with the study
Exclusion criteria
Exclusion criteria: Pregnancy or Breastfeeding Hb less than 9mg/dl Leukocyte less than 4000 Platelet less than 100000 Potassium is less than 3.5 Liver enzymes 2 times more than the reference limit ESR above reference limit Positive Stool Test for Strongyloides stercoralis Positive tests for viral hepatitis Use of any systemic drug a month before the start of the study There is a contraindication for betamethasone (diabetes, high blood pressure, drug allergy, active infection, recent surgery history, osteoporosis, stomach ulcer and psychosis, or depression) Sensitivity to methotrexate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Photographic Scoring for patients with Alopecia Areata. Timepoint: Before the start of the study and 3 , 6, 9 months after the start of treatment. Method of measurement: Photographic Scoring.;Visual Analogue Scale Score in patient with Alopecia Areata. Timepoint: Before the start of the study and 3 , 6, 9 months after the start of treatment. Method of measurement: Visual Analogue Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZakiye Ganjei
Esfahan University of Medical Sciences
Outcome results
None listed